# NCT02500407 (NCT02500407)

> A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02500407
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Lymphocytic Leukemia, Chronic; Lymphoma, Non Hodgkin
- Interventions: BTCT4465A (Mosunetuzumab) IV; Atezolizumab; BTCT4465A (Mosunetuzumab) SC
- Enrollment: 713
- Primary outcome: Maximum Tolerated Dose (MTD) of BTCT4465A (Mosunetuzumab)
- Primary outcome: Percentage of Participants With Adverse Events
- Primary outcome: BTCT4465A (Mosunetuzumab) Serum Concentration
- Primary outcome: Atezolizumab Serum Concentration
- Primary outcome: Percentage of Participants with Complete Response as Assessed Using Standard Criteria for NHL

## Indexed commentary on NCT02500407 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02500407